Melling, Nathaniel, Norrenbrock, Sonja, Kluth, Martina, Simon, Ronald, Hube-Magg, Claudia, Steurer, Stefan, Hinsch, Andrea, Burandt, Eike, Jacobsen, Frank, Wilczak, Waldemar, Quaas, Alexander, Bockhorn, Maximillian, Grupp, Katharina, Tachezy, Michael, Izbicki, Jakob, Sauter, Guido and Gebauer, Florian (2019). p53 overexpression is a prognosticator of poor outcome in esophageal cancer. Oncol. Lett., 17 (4). S. 3826 - 3835. ATHENS: SPANDIDOS PUBL LTD. ISSN 1792-1082

Full text not available from this repository.

Abstract

Immunohistochemistry studies on p53 inactivation in esophageal cancer are available with inconclusive results. Data on the combined effect of p53 protein accumulation and TP53 genomic deactivation in large scale studies for esophageal cancer are currently lacking. A tissue microarray with 691 esophageal cancer samples was analyzed by p53 immunohistochemistry and fluorescence in situ hybridization (FISH). Nuclear p53 accumulation was observed in 45.9% of patients with adenocarcinoma (AC) and in 40.0% in squamous cell carcinoma (SCC). Heterozygous TP53 deletions occurred in 40.9% in AC and in 19.4% in SCC. Homozygous deletions did not occur at all. High-level p53 immunostaining was associated with shortened overall survival in AC and SCC while TP53 deletions alone showed no correlation with survival. High-level p53 immunostaining in patients with AC was associated with advanced tumor (P=0.019) and Union for International Cancer Control stages (P=0.004), grading (P=0.027) and the resection margin status (P=0.006). Associations between p53 immunostaining and SCC were not found. TP53 deletions were found to be associated with advanced tumor stages (P=0.028) and the presence of lymph node metastasis (P=0.009) in SCC. In conclusion, strong p53 immunostaining, but not TP53 deletion alone, is associated with unfavorable outcomes and may therefore represent a clinically useful molecular marker in esophageal cancer.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Melling, NathanielUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Norrenbrock, SonjaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kluth, MartinaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Simon, RonaldUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hube-Magg, ClaudiaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Steurer, StefanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hinsch, AndreaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Burandt, EikeUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Jacobsen, FrankUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wilczak, WaldemarUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Quaas, AlexanderUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bockhorn, MaximillianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Grupp, KatharinaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Tachezy, MichaelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Izbicki, JakobUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sauter, GuidoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gebauer, FlorianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-152757
DOI: 10.3892/ol.2019.10020
Journal or Publication Title: Oncol. Lett.
Volume: 17
Number: 4
Page Range: S. 3826 - 3835
Date: 2019
Publisher: SPANDIDOS PUBL LTD
Place of Publication: ATHENS
ISSN: 1792-1082
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
SQUAMOUS-CELL CARCINOMA; EXPRESSION; MUTATION; ASSOCIATION; PROGRESSION; PROGNOSIS; SURVIVAL; DELETIONMultiple languages
OncologyMultiple languages
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/15275

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item